Literature DB >> 27514248

Increasing reach by offering choices: Results from an innovative model for statewide services for smoking cessation.

Paula A Keller1, Barbara A Schillo2, Amy N Kerr3, Rebecca K Lien4, Jessie Saul5, Marietta Dreher6, Randi B Lachter7.   

Abstract

Although state quitlines provide free telephone counseling and often include nicotine replacement therapy (NRT), reach remains limited (1-2% in most states). More needs to be done to engage all smokers in the quitting process. A possible strategy is to offer choices of cessation services through quitlines and to reduce registration barriers. In March 2014, ClearWay MinnesotaSM implemented a new model for QUITPLAN® Services, the state's population-wide cessation services. Tobacco users could choose the QUITPLAN® Helpline or one or more Individual QUITPLAN® Services (NRT starter kit, text messaging, email program, or quit guide). The program website was redesigned, online enrollment was added, and a new advertising campaign was created and launched. In 2014-2015, we evaluated whether these changes increased reach. We also assessed quit attempts, quit outcomes, predictors of 30-day abstinence, and average cost per quit via a seven-month follow-up survey. Between March 2014-February 2015, 15,861 unique tobacco users registered, which was a 169% increase over calendar year 2013. The majority of participants made a quit attempt (83.7%). Thirty-day point prevalence abstinence rates (responder rates) were 26.1% for QUITPLAN Services overall, 29.6% for the QUITPLAN Helpline, and 25.5% for Individual QUITPLAN Services. Several variables predicted quit outcomes, including receiving only one call from the Helpline and using both the Helpline and the NRT starter kit. Providing greater choice of cessation services and reducing registration barriers have the potential to engage more tobacco users, foster more quit attempts, and ultimately lead to long-term cessation and reductions in prevalence.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27514248     DOI: 10.1016/j.ypmed.2016.08.010

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  6 in total

1.  Adaptive interventions to optimise the mobile phone-based smoking cessation support: study protocol for a sequential, multiple assignment, randomised trial (SMART).

Authors:  Sheng Zhi Zhao; Xue Weng; Tzu Tsun Luk; Yongda Wu; Derek Yee Tak Cheung; William Ho Cheung Li; Henry Tong; Vienna Lai; Tai Hing Lam; Man Ping Wang
Journal:  Trials       Date:  2022-08-18       Impact factor: 2.728

2.  COVID-19 and Tweets About Quitting Cigarette Smoking: Topic Model Analysis of Twitter Posts 2018-2020.

Authors:  J Lee Westmaas; Matthew Masters; Priti Bandi; Anuja Majmundar; Samuel Asare; W Ryan Diver
Journal:  JMIR Infodemiology       Date:  2022-05-16

3.  Effectiveness of Pharmaceutical Smoking Cessation Aids in a Nationally Representative Cohort of American Smokers.

Authors:  Eric C Leas; John P Pierce; Tarik Benmarhnia; Martha M White; Madison L Noble; Dennis R Trinidad; David R Strong
Journal:  J Natl Cancer Inst       Date:  2018-06-01       Impact factor: 13.506

Review 4.  Review of Evaluation Metrics Used in Digital and Traditional Tobacco Control Campaigns.

Authors:  Lilian Chan; Blythe O'Hara; Philayrath Phongsavan; Adrian Bauman; Becky Freeman
Journal:  J Med Internet Res       Date:  2020-08-11       Impact factor: 5.428

5.  Reach and effectiveness of the NCI Cancer Moonshot-funded Cancer Center Cessation Initiative.

Authors:  Heather D'Angelo; Sarah D Hohl; Betsy Rolland; Robert T Adsit; Danielle Pauk; Michael C Fiore; Timothy B Baker
Journal:  Transl Behav Med       Date:  2022-05-26       Impact factor: 3.626

6.  Replicating state Quitline innovations to increase reach: findings from three states.

Authors:  Paula A Keller; Rebecca K Lien; Laura A Beebe; Jane Parker; Paola Klein; Randi B Lachter; Stephen Gillaspy
Journal:  BMC Public Health       Date:  2020-01-06       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.